Anti-HE4 antibodies in infertile women and women with ovarian cancer

Gynecologic Oncology

Volumn 130, Issue 3, 2013, Pages 629-633

  Hellstrom, Ingegerd ^a   Swisher, Elizabeth ^b   Hellstrom, Karl Erik ^a   Yip, Yuen Yee ^a   Agnew, Kathy ^b   Luborsky, Judith L ^c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Cancer diagnostics; Inflammation; Tumor antigens

Indexed keywords

CANCER ANTIBODY; HE4 ANTIBODY; MESOTHELIN; UNCLASSIFIED DRUG;

ADULT; ANTIBODY DETECTION; ARTICLE; CANCER PATIENT; CANCER RISK; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEMALE INFERTILITY; HUMAN; OVARY CANCER; OVARY INSUFFICIENCY; PRIORITY JOURNAL;

CANCER DIAGNOSTICS; INFLAMMATION; TUMOR ANTIGENS;

ADOLESCENT; ADULT; ANTIBODIES; ANTIGENS; CASE-CONTROL STUDIES; ENDOMETRIOSIS; FEMALE; GPI-LINKED PROTEINS; HUMANS; INFERTILITY, FEMALE; OVARIAN NEOPLASMS; OVULATION; PRIMARY OVARIAN INSUFFICIENCY; PROTEINS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84882454283     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.05.028     Document Type: Article

References (43)

1. S. Gnjatic, E. Ritter, M.W. Büchler, N.A. Giese, B. Brors, and C. Frei Seromic profiling of ovarian and pancreatic cancer Proc Natl Acad Sci U S A 107 11 2010 5088 5093
2. M. Reuschenbach, M. von Knebel, Doeberitz, and N. Wentzensen A systematic review of humoral immune responses against tumor antigens Cancer Immunol Immunother 58 10 2009 1535 1544
3. R. Bei, L. Masuelli, C. Palumbo, M. Modesti, and A. Modesti A common repertoire of autoantibodies is shared by cancer and autoimmune disease patients: Inflammation in their induction and impact on tumor growth Cancer Lett 281 1 2009 8 23
4. E. Stockert, E. Jäger, Y.T. Chen, M.J. Scanlan, I. Gout, and J. Karbach A survey of the humoral immune response of cancer patients to a panel of human tumor antigens J Exp Med 187 8 1998 1349 1354
5. M. Nesterova Autoantibody biomarker opens a new gateway for cancer diagnosis Biochim Biophys Acta 1762 4 2006 398 403
6. E.M. Tan, and J. Zhang Autoantibodies to tumor-associated antigens: reporters from the immune system Immunol Rev 222 2008 328 340
7. J.L. Luborsky, A. Barua, S.V. Shatavi, T. Kebede, J. Abramowicz, and J. Rotmensch Anti-tumor antibodies in ovarian cancer Am J Reprod Immunol 54 2005 55 62
8. T. Ramirez-Montagut, M.J. Turk, J.D. Wolchok, J.A. Guevara-Patino, and A.N. Houghton Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity Oncogene 22 20 2003 3180 3187
9. H. Uchi, R. Stan, M.J. Turk, M.E. Engelhorn, G.A. Rizzuto, and S.M. Goldberg Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo Adv Immunol 90 2006 215 241
10. F. Balkwill, and A. Mantovani Inflammation and cancer: back to Virchow? Lancet 357 9255 2001 539 545
11. L.M. Coussens, and Z. Werb Inflammation and cancer Nature 420 6917 2002 860 867
12. S.I. Grivennikov, F.R. Greten, and M. Karin Immunity, inflammation, and cancer Cell 140 6 2010 883 899
13. T.M. Azar KK, H. Yasuda, A. Sakai, M. Inoue, and T. Sasagawa Increased secretion patterns of interleukin-10 and tumor necrosis factor-alpha in cervical squamous intraepithelial lesions Hum Pathol 35 11 2004 1376 1384
14. Q. Feng, H. Wei, J. Morihara, J. Stern, M. Yu, and N. Kiviat Th2 type inflammation promotes the gradual progression of HPV-infected cervical cells to cervical carcinoma Gynecol Oncol 127 2 2012 412 419
15. S. Edassery, S.V. Shatavi, J.P. Kunkel, C. Hauer, C. Brucker, and K. Penumatsa Autoanigens in ovarian autoimmunity associated with unexplained infertility and premature ovarian failure Fertil Steril 94 2010 2636 2641
16. B.C. Vanderhyden Loss of ovarian cancer fuanction and the risk for ovarian cancer Cell Tissue Res 322 2005 117 124
17. E. Smith, and X. XX Ovarian ageing, follicle depletion, and cancer: a hypothesis for the aetiology of epithelial ovarian cancer involving follicle depletion Lancet Oncol 9 2008 1108 1111
18. A. Barua, M.J. Bradaric, T. Kebede, S. Espionosa, S.L. Edassery, and P. Bitterman Anti-ovarian and anti-tumor antibodies in women with ovarian cancer Am J Reprod Immunol 57 2007 243 249
19. I. Hellstrom, and K.E. Hellstrom Two new biomarkers, mesothelin and HE4, for diagnosis of ovarian carcinoma Expert Opin Med Diagn 5 2011 227 240
20. M.H. Ho, R. Hassan, J. Zhang, Q.C. Wang, M. Onda, and T. Bera Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients Clin Cancer Res 11 2005 3814 3820
21. I. Hellstrom, E. Friedman, T. Verch, Y. Yang, J. Korach, and J. Jaffar Anti-mesothelin antibodies and circulating mesothelin relate to the clinical state in ovarian cancer patients Cancer Epidemiol Biomarkers Prev 17 2008 1520 1526
22. H.W. Lin, Y.Y. Tu, S.Y. Lin, W.J. Su, W.L. Lin, and W.Z. Lin Risk of ovarian cancer in women with pelvic inflammatory disease: a population-based study Lancet Oncol 112 2011 900 904
23. J.L. Luborsky, Y. Yu, S.L. Edassery, J. Jaffar, Y.Y. Yip, and P. Liu Autoantibodies to mesothelin in infertility Cancer Epidemiol Biomarkers Prev 20 2011 1970 1978
24. C. Kirchhoff, I. Habben, R. Ivell, and N. Krull A major human epididymis-specific cDNA encodes a protein with sequence homology to extracellular proteinase inhibitors Biol Reprod 45 1991 350 357
25. M. Schummer, W.V. Ng, R.E. Bumgarner, P.S. Nelson, B. Schummer, and D.W. Bednarski Comparative hybridization of an array of 21,500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas Gene 238 2 1999 375 385
26. I. Hellstrom, J. Raycraft, M. Hayden-Ledbetter, J.A. Ledbetter, M. Schummer, and M. McIntosh The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma Cancer Res 63 13 2003 3695 3700
27. L. Bingle, S.S. Cross, A.S. High, W.A. Wallace, D. Rassl, and G. Yuan WFDC2 (HE4): a potential role in the innate immunity of the oral cavity and resiratory tract in the development of adenocarcinomas of the lung Respir Res 7 2006 61 80
28. R.G. Moore, A.K. Brown, M.C. Miller, D. Badgwell, Z. Lu, and W.J. Allard Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus Gynecol Oncol 110 2008 196 201
29. R.G. Moore, A.K. Brown, M.C. Miller, S. Skates, W.J. Allard, and T. Verch The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass Gynecol Oncol 108 2008 402 408
30. R.G. Moore, D.S. McMeekin, A.K. Brown, P. DiSilvestro, M.C. Miller, and W.J. Allard A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass Gynecol Oncol 112 2009 40 46
31. H. Wei, P. Liu, E. Swisher, Y.Y. Yip, J.H. Tse, and K. Agnew Silencing of the TGFbeta1 gene increases the immunogenicity of cells from human ovarian carcinoma J Immunother 35 2012 267 275
32. F. Broekmans, and B. Fauser Diagnostic criteria for polycystic ovarian syndrome Endocrine 30 2006 3 11
33. S.K. Ng, D. Wang, and Y. Mg Application of destabilizing sequences on selection marker for improved recombinant protein productivity in CHO-DG44 Metab Eng 9 2007 304 316 [Epub 2007 Feb 14]
34. M. Reuschenbach, M. von Knebel, Doeberitz, and N. Wentzensen A systematic review of humoral immune responses against tumor antigens Cancer Immunol Immunother 58 2009 1535 1544
35. K. Huhtinen, P. Suvitie, J. Hiissa, J. Junnila, J. Huvila, and H. Kujari Serum HE4 concentrations differentiatesd malignant ovarian tumours from ovarian endometriotic cysts Br J Cancer 100 2009 1315 1319
36. M. Kobel, S.E. Kalloger, N. Boyd, S. McKinney, E. Mehl, and C. Palmer Ovarian carcinoma subtypes are different diseases: implications for biomarker studies PLoS Med 5 12 2008 e232 10.1371/journal.pmed.0050232
37. J. Luborsky Ovarian autoimmune disease and ovarian autoantibodies J Womens Health Gend Based Med 11 2002 585 599
38. D.G. DeNardo, J.B. Barreto, P. Andreu, L. Vasquez, D. Tawfik, and N. Kolhatkar CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages Cancer Cell 16 2 2009 91 102
39. M. Thornquist, G.S. Omenn, G.E. Goodman, J.E. Grizzle, L. Rosenstock, and S. Barnhart Statistical design and monitoring of the Carotene and Retinol Efficacy Trial (CARET) Control Clin Trials 14 1993 308 324
40. G.L. Anderson, M. McIntosh, L. Wu, M. Barnett, G. Goodman, and J.D. Thorpe Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study J Natl Cancer Inst 102 2010 26 38
41. I. Hellstrom, P.J. Heagerty, E.M. Swisher, P. Liu, J. Jaffar, and K. Agnew Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms Cancer Lett 296 2010 43 48
42. D. Badgwell, Z. Lu, L. Cole, H. Fritsche, E.N. Atkinson, and E. Somers Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment Gynecol Oncol 106 2008 490 497
43. I. Hellstrom, and K.E. Hellstrom SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other Adv Exp Med Biol 622 2008 15 21